Form 4 for DSS DSS, INC.

Accepted 2024-01-02 00:00:00 ET · period of report 2023-12-28 · accession 0001493152-24-000039 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2024-01-02	2023-12-28	DSS	Chan Heng Fai Ambrose	Dir, 10%	P - Purchase	$0.15	+672.2K	19.59M	+4%	+$100.8K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-12-28	P	A	672,173	$0.15	19,586,499	D	—	—	(F1) On December 28, 2023, the reporting person purchased 672,173 shares of the Issuer's common stock. This transaction was executed in multiple trades at prices ranging from $0.1239 to $0.15. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. (F2) The beneficial ownership of Heng Fai Chan includes a total of 82,458,315 shares of common stock, consisting of (a) 59,552 shares of common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 19,586,499 shares of common stock held by Heng Fai Chan directly; (c) 35,213,416 shares of common stock held by Alset Inc., an entity controlled by Mr. Chan; (d) 21,366,177 shares of common stock held by Alset International Limited, an entity controlled by Mr. Chan and a subsidiary of Alset Inc.; and (e) 6,232,671 shares of common stock held by Global Biomedical Pte. Ltd., an entity controlled by Mr. Chan and a subsidiary of Alset International Limited.